TheraRadar
Clinical-Stage Companies / Caliway Biopharmaceuticals

Caliway Biopharmaceuticals

Pre-Approval PRO BETA
16
Total Trials
3
Phase 3
12
Phase 2
2
Recruiting
169
Score

Pipeline by Phase

Phase 3
3
Phase 2
12
Phase 1
1

Therapeutic Focus

Subcutaneous Fat Dercum's Disease Cellulite

Clinical Trials (16)

NCT07526974 Phase 3 NOT YET RECRUITING

A Study to Evaluate the Efficacy and Safety of CBL-514 Injection for Reducing Subcutaneous Fat ( SUPREME-02 )

Started: 10/1/2026

NCT07140939 Phase 3 NOT YET RECRUITING

A Study to Evaluate the Efficacy and Safety of CBL-514 Injection for Reducing Subcutaneous Fat

Started: 7/1/2026

NCT07733947 Phase 3 NOT YET RECRUITING

A Study to Evaluate the Maintenance of Efficacy and Long-term Safety of CBL-514 Injection for Reducing Subcutaneous Fat (Stage 1)

Started: 12/1/2026

NCT07608770 Phase 2 RECRUITING

A Study to Evaluate the Efficacy, Safety, and Tolerability of CBL-514 Injection for Reducing Abdominal Subcutaneous Fat

Started: 6/1/2026

NCT06303570 Phase 2 ACTIVE NOT RECRUITING

A Study to Evaluate the Efficacy and Safety of CBL-514 Compared to Placebo in Participants With Dercum's Disease Lipomas

Started: 11/27/2024

NCT06005441 Phase 2 COMPLETED

A Phase 2b Study to Evaluate the Efficacy and Safety of CBL-514 Injection for Reducing Subcutaneous Fat.

Started: 11/10/2023

NCT04575467 Phase 2 COMPLETED

A Study to Evaluate the Efficacy, Safety and Tolerability of CBL-514 Injection for Reducing Subcutaneous Fat (Stage 1)

Started: 12/9/2020

NCT05736107 Phase 2 COMPLETED

A Study to Evaluate the Efficacy, Safety and Tolerability of CBL-514 Injection for Reducing Abdominal Subcutaneous Fat

Started: 5/30/2023

NCT05836779 Phase 2 COMPLETED

A Study to Evaluate the Efficacy and Safety of CBL-514 in Participants With EFP; Cellulite (Stage 2)

Started: 5/10/2023

NCT05632926 Phase 2 COMPLETED

A Study to Evaluate the Efficacy and Safety of CBL-514 in Participants With EFP; Cellulite (Stage 1)

Started: 1/9/2023

NCT04897412 Phase 2 COMPLETED

A Study to Evaluate the Efficacy, Safety, and Tolerability of CBL-514 Injection for Reducing Subcutaneous Fat (Stage 2)

Started: 2/14/2022

NCT05387733 Phase 2 COMPLETED

A Study to Evaluate the Efficacy and Safety of CBL-514 in Participants With Dercum's Disease Lipomas

Started: 10/3/2022

NCT05234736 Phase 2 COMPLETED

A Study to Evaluate the Pharmacokinetic Profile of CBL-514 Injection in Healthy Volunteers

Started: 2/11/2022

NCT04698642 Phase 2 COMPLETED

A Study to Evaluate the Safety, Tolerability, and Preliminary Efficacy of CBL-514 Injection for Reducing Convexity or Fullness of Abdominal Subcutaneous Fat

Started: 2/3/2020

NCT07608757 Phase 2 NOT YET RECRUITING

A Study to Evaluate the Efficacy, Safety, and Tolerability of CBL-514 Injection for Reducing Abdominal Subcutaneous Fat

Started: 2/1/2027

NCT04699669 Phase 1 COMPLETED

A Phase 1 Study to Evaluate the Safety and Tolerability of CBL-514 Injection on Convexity or Fullness of Abdominal Subcutaneous Fat in Healthy Volunteers

Started: 11/27/2018

Drug Candidates

CBL-514 Injection CBL-514 injection CBL-A1 Injection CBL-A2 Injection CBL-514
Activity Status: Active
Last Trial Started: 2/1/2027
Last Trial Ended: 10/18/2024
Trials (12 months): 5
Completed Trials: 10
Data sourced from ClinicalTrials.gov. This company has no FDA-approved drugs.